WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46
E-mail:
 
Copyright/Disclaimer

Overview of new ATC codes decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC codes will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the list does not include new ATC codes established as a result of ATC alterations.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code 1) Implementation in the ATC/DDD index
A03FA08cinitapride01.09.20162017
A04AD14rolapitant01.09.20162017
A06AH04naloxone 01.09.20162017
A07DA06eluxadolineFinal2017
A16AA07metreleptinFinal2017
A16AX12trientineFinal2017
A16AX13uridine triacetate 01.09.20162017
B01AF03edoxabanFinal2017
B03AB10ferric maltolFinal2017
C01BA13hydroquinidine01.09.20162017
C01EB23tiazotic acidFinal2017
C07AB14landiololFinal2017
C07FX05metoprolol and ivabradineFinal2017
C07FX06carvedilol and ivabradineFinal2017
C10AX14alirocumabFinal2017
C10BX12atorvastatin, acetylsalicylic acid and perindopril 01.09.20162017
D03AX13Betulae cortex01.09.20162017
D11AX23aminobenzoate potassiumFinal2017
D11AX24deoxycholic acidFinal2017
G03GA10follitropin deltaFinal2017
G04BD13desfesoterodineFinal2017
H05BX04etelcalcetideFinal2017
J01FA16solithromycin01.09.20162017
J05AF13tenofovir alafenamide01.09.20162017
J05AX68elbasvir and grazoprevirFinal2017
J06BB21bezlotoxumab01.09.20162017
L01XC23elotuzumabFinal2017
L01XC24daratumumabFinal2017
L01XC25mogamulizumabFinal2017
L01XC26inotuzumab ozogamicinFinal2017
L01XE35osimertinibFinal2017
L01XE36alectinibFinal2017
L01XE37rociletinibFinal2017
L01XE38cobimetinibFinal2017
L01XE39midostaurin01.09.20162017
L01XE40olmutinib01.09.20162017
L01XX51talimogene laherparepvecFinal2017
L01XX52 venetoclax 01.09.20162017
L01XX53vosaroxin01.09.20162017
L03AA16empegfilgrastimFinal2017
L04AA36ocrelizumab01.09.20162017
L04AA37baricitinib01.09.20162017
L04AC13ixekizumabFinal2017
L04AC14sarilumab01.09.20162017
M02AA28piketoprofen01.09.20162017
M05BX05burosumab01.09.20162017
M09AX05aceneuramic acidFinal2017
N02AJ14tramadol and dexketoprofenFinal2017
N02AJ15tramadol and other non-opioid analgesics01.09.20162017
N04BD03safinamideFinal2017
N05AX17 pimavanserin01.09.20162017
N05BA24bentazepam01.09.20162017
P01BX02arterolane and piperaquineFinal2017
R03AK13salbutamol and beclometasoneFinal2017
R03AL07 formoterol and glycopyrronium bromide01.09.20162017
S01FB51phenylephrine and ketorolacFinal2017
V03AE09 patiromer calcium 01.09.20162017
V04CE03methacetin (13C)01.09.20162017
V09IX09gallium (68Ga) edotreotideFinal2017
V09IX10fluoroethyl-L-tyrosine (18F)Final2017
V09IX11fluoroestradiol (18F)01.09.20162017
V09IX12Fluciclovine (18F)01.09.20162017
1) Final: indicates that the date for objection has expired.

Last updated: 2016-06-07